ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0122

Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial

Stephanie Catella1, Michael Gendreau2, Nicolette Vega1, Allison Kraus1, Michael Rosenbluth1, Sherry Soefje3, Shishuka Malhotra4 and Lesley Arnold5, 1Swing Therapeutics, San Francisco, CA, 2Gendreau Consulting, LLC, Poway, CA, 3Excell Research, Oceanside, CA, 4Neuro-Behavioral Clinical Research, North Canton, OH, 5University of Cincinnati, Cincinnati, OH

Meeting: ACR Convergence 2021

Keywords: fibromyalgia, health behaviors, physical function, quality of life, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Recommendations for fibromyalgia management include both pharmacologic and nonpharmacologic treatments. Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for fibromyalgia management, though access is limited due to few trained clinicians and cost. An at home digital behavioral therapy could significantly increase access.

A smartphone-based Acceptance and Commitment Therapy (ACT) program was developed for fibromyalgia management. ACT is a modern type of CBT increasingly used to manage chronic pain that focuses on acceptance of uncontrollable and untreatable symptoms. A multi-site study is underway to understand the feasibility of a largely virtual study and determine the impact of smartphone-delivered ACT compared to a digital active control.

Methods: Participants diagnosed with fibromyalgia using 2016 criteria were randomized to digital ACT or an active control. Participants remained stable on other ongoing fibromyalgia treatment. The digital ACT intervention consists of 41 daily sessions of structured ACT lessons, mindfulness practices, and activities to encourage paced exercise and behavior change. An active control was implemented to account for study engagement and expectation biases. Components of the active control (Symptom Tracker, or ST) include daily symptom tracking and monitoring and access to patient education. During the 12 week study, participants were expected to use the smartphone applications at least 5 days a week.

FIQ-R, the primary outcome, was administered weekly. Secondary outcomes include PGIC, weekly recall pain intensity and interference, and sleep quality (NRS), BDI-II, PROMIS-29, Five Facets of Mindfulness, and Psychological Inflexibility in Pain Scale.

The study has enrolled 67 participants. Twenty-seven participants have completed the study to date and 22 are included in the current analysis set (Figure 1).

Results: The characteristics of the participants are summarized in Table 1. Engagement in both arms is high throughout the study (an average completion of 5 sessions per week in each arm).

Improvement of 20% or greater in total FIQR score was observed in 50% of the ACT group compared to 25% in the ST group. Participants in ACT improved on average 10.5 points (20%) in total FIQR score compared to 4.8 points (9%) in ST. Forty percent of ACT participants reported “much improved” or greater on the PGIC compared to 0% in ST. More improvement was seen in ACT over ST in most other outcome measures. No treatment related adverse events have been observed. This study is ongoing and full results are expected this summer.

Conclusion: A mostly virtual digital therapy study is feasible with high engagement in both ACT and the active control. Participants in the ACT arm achieved greater reductions on FIQ-R and showed greater improvement on PGIC compared to ST. Participants in the ACT arm showed greater improvement relative to the ST arm on ACT process measures, suggesting digital ACT is effectively targeting therapeutic processes of change.

The findings suggest that digital ACT may improve fibromyalgia management and appears to be well tolerated.

Figure 1. Flow of participants in the SMART-FM study (Consort diagram).

Table 1. Background characteristics of study participants.


Disclosures: S. Catella, Swing Therapeutics, 7; M. Gendreau, Tonix Pharmaceuticals, 2, Dare Biosciences, 2, Bionomics Limited, 2, Teva Pharmaceuticals, 2, Virios Theraoeutics, 4, 11, Swing Therapeutics, 1, 2, 11; N. Vega, Swing Therapeutics, Inc., 3, 11, Stryker Corp, 3; A. Kraus, Swing Therapeutics, 3, 11; M. Rosenbluth, Swing Therapeutics, 3, 8; S. Soefje, Swing Therapeutics, 12, Contracted clinical research site; S. Malhotra, None; L. Arnold, Pfizer, 2, 5, Teva, 2, 5, Jazz, 2, Lundbeck, 2, Eliem, 2, AbbVie, 5, Tonix, 5, Swing Therapeutics, 5, Aptinyx, 2, 5, Virios Therapeutics, 2, 5, Otsuka, 5.

To cite this abstract in AMA style:

Catella S, Gendreau M, Vega N, Kraus A, Rosenbluth M, Soefje S, Malhotra S, Arnold L. Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/clinical-impact-of-a-digital-behavioral-therapy-for-fibromyalgia-management-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-impact-of-a-digital-behavioral-therapy-for-fibromyalgia-management-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology